Clearside Biomedical Inc

Clearside Biomedical — Investor Presentation (May 2019)

37 slides from Clearside Biomedical's investor presentation, May 22, 2019

  1. Slide 1: Corporate Presentation | May 2019

    Corporate Presentation | May 2019 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,”

  3. Slide 3: Clearside Biomedical Overview

    Clearside Biomedical Overview Dedicated to developing treatments that restore and preserve vision for people with serious eye diseases Novel, therapeutic platform combines patented suprachoroidal space injection technology with a proprietary drug formulation Validating platform with first potential

  4. Slide 4: Proprietary Approach to Treating Eye Diseases

    Therapeutics: Small Molecules Biologics Gene Therapy Proprietary Approach to Treating Eye Diseases Clearside Suprachoroidal Space Injection Platform Suprachoroidal Space (SCS) Device: SCS Microinjector™

  5. Slide 5: Exclusive and Proprietary Access to the Back of the Eye

    Exclusive and Proprietary Access to the Back of the Eye

  6. Slide 6: Differences in Procedures to Reach the Back of the Eye

    Differences in Procedures to Reach the Back of the Eye Suprachoroidal Space (SCS) Injection Fluid flows instantaneously and posteriorly Consistent suprachoroidal injection procedure Fluid with drug is absorbed into the choroid, retina, and retinal pigment epithelium (RPE) Intravitreal Injection Broa

  7. Slide 7: Novel Treatment Opportunities Via the Suprachoroidal Space

    Novel Treatment Opportunities Via the Suprachoroidal Space (SCS) References: 1. Rai UDJ, Young SA, Thrimawithana TR, et al. The suprachoroidal pathway: a new drug delivery route to the back of the eye. Drug Discov Today. 2015;20(4):491-495. 3. Moisseiev E, Loewenstein A, Yiu G. The suprachoroidal sp

  8. Slide 8: Strong Intellectual Property Coverage of SCS Platform

    15 Apparatus using loss-of-resistance technology Administration of any anti-inflammatory drug to the suprachoroidal space by microinjection Methods of treating macular edema or uveitis Methods using loss-of-resistance technology Apparatus having / methods using an adjustable puncture member Administ

  9. Slide 9: Pipeline of SCS Treatments with Broad Applicability

    INDICATION STUDY DRUG CURRENT STATUS Uveitis (macular edema associated with uveitis) XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection DME (diabetic macular edema) XIPERE™ Wet AMD Undisclosed DME Undisclosed Inherited Retinal Diseases Gene Therapy Pipeline of SCS T

  10. Slide 10: The Opportunity: Macular Edema Associated with Uveitis

    The Opportunity No approved treatment for macular edema associated with uveitis All anatomic locations of uveitis included in Clearside clinical trials ~50% of patients continue to have macular edema, even after a course of treatment for non-infectious uveitis Macular Edema Associated with Uveitis P

  11. Slide 11: Market Size and Current Treatment Paradigm for Uveitis

    Market Size and Current Treatment Paradigm for Uveitis 350,000 patients US uveitis patients ~115,500 patients 33-47% macular edema 210,000 eyes 82% disease in both eyes Corticosteroid Drops CURRENT TREATMENTS Intravitreal triamcinolone acetonide (TA) LOCAL INJECTIONS TOPICAL Sub-tenon TA Sustained r

  12. Slide 12: Novel Approach to Targeting Uveitic Macular Edema

    Pivotal Phase 3 PEACHTREE trial met its primary endpoint NDA submitted in Q4 2018 with October 19, 2019 PDUFA date If approved, XIPERE would be the first therapy for this indication If approved, commercial launch for XIPERE anticipated in Q1 2020 Novel Approach to Targeting Uveitic Macular Edema XIP

  13. Slide 13: Designed to Improve Ocular Distribution of Triamcinolone Acetonide

    Concentration (ng/g) Time, days Designed to Improve Ocular Distribution of Triamcinolone Acetonide (TA) The anterior segment is relatively spared following suprachoroidal dosing when compared to intravitreal dosing Over 10X the amount of TA remaining in the choroid and RPE following suprachoroidal a

  14. Slide 14: PEACHTREE: Pivotal Phase Clinical Trial in Non-Infectious Uveitis

    PEACHTREE: Pivotal Phase 3 Clinical Trial for Macular Edema Associated with Non-Infectious Uveitis (NIU) 3:2 randomization of XIPERE vs. sham injection; 160 subjects total Primary endpoint at 6 months; proportion of patients gaining three lines of vision compared to sham CONTROL Week-2 Day 0 Day 0 W

  15. Slide 15: PEACHTREE Met Its Primary Endpoint

    46.9% (n=45) 15.6% (n=10) % patients gaining ≥15 ETDRS letters in BCVA from baseline Proportion of patients in each arm gaining ≥ 15 ETDRS letters in BCVA from baseline at Week 24 p<0.001 N=96 N=64 PEACHTREE Met Its Primary Endpoint ETDRS = Early Treatment Diabetic Retinopathy Study | BCVA = Best Co

  16. Slide 16: PEACHTREE Met Its Secondary Endpoint

    Mean change from baseline at week 24 in central retinal thickness (microns) 480.9 µm: active arm; 525.4 µm: control arm p<0.001 Baseline retinal thickness (microns) N=96 N=64 Intention-to-treat (ITT) PEACHTREE Met Its Secondary Endpoint Mean Change from Baseline in CST at Week 24 in Microns Source:

  17. Slide 17: Vision Gained Rapidly and Sustained Through Week 24

    Baseline ETDRS letters read 54.7: active arm; 53.5: control arm Mean change at each visit from baseline in BCVA in ETDRS letters read p<0.001 Vision Gained Rapidly and Sustained Through Week 24 Mean Change in BCVA in ETDRS Letters by Visit Source: Phase 3 PEACHTREE data BCVA = Best Corrected Visual

  18. Slide 18: Resolved Inflammation in ~70% of Patients in PEACHTREE

    % patients with scores of zero at week 24 Resolution of each of these three signs of inflammation on the SUN* scales is clinically and statistically significant In subjects with scores of 2 or greater in vitreous haze, 40.9% experienced resolution in the active arm, compared to 0% of subjects in the

  19. Slide 19: Favorable Intraocular Pressure (IOP) Profile

    IOP lowering medications were initiated in 7.3% and 9.4% subjects in the XIPERE and control arms respectively Favorable Intraocular Pressure (IOP) Profile Compared to Patients Rescued with Local Corticosteroids AE = adverse event “Elevated IOP” includes (a) increased IOP, (b) ocular hypertension, an

  20. Slide 20: Cataract Adverse Events Were Balanced Between Arms

    Percentage of Cataract Adverse Events (AEs) Were Balanced Between Arms Percentage of cataract AEs Mar-2018 | NIU program | P3, PEACHTREE, trial | Topline data

  21. Slide 21: MAGNOLIA: Observational 24 Week Extension Trial

    To be eligible for MAGNOLIA, subjects must have completed PEACHTREE and NOT have received rescue medication Primary Endpoint: Time to rescue therapy relative to Day 0 of PEACHTREE MAGNOLIA: Prospective, Non-interventional, Masked, Observational 24 week Extension Trial Day 0 Week 4 Week 8 Week 12 Wee

  22. Slide 22: Magnolia Extension Study Demonstrates Positive Efficacy and Durability Results

    Efficacy 50% of patients did not receive additional medication through week 48 Results were durable for 36 weeks after last injection of XIPERE Suprachoroidally injected XIPERE significantly improved vision (~12 letters) and macular edema (~170 microns) Safety There were no Serious AEs related to st

  23. Slide 23: XIPERE Launch Preparations

    XIPERE Launch Preparations PHYSICIANS Education materials Injection training Patient access support PATIENTS Education materials Reimbursement support services PAYERS Proactive education on uveitic macular edema as an unmet need

  24. Slide 24: Physicians Recognize the Unmet Need and Favorable Reaction to XIPERE

    Physicians Recognize the Unmet Need and Over 90% Had a Favorable Reaction to the XIPERE Profile Source: Target Ophthalmologist ATU, May 2018

  25. Slide 25: Payers Believe XIPERE Helps Fill the Unmet Need

    Payers Believe XIPERE Helps Fill the Unmet Need in Uveitic Macular Edema Payers View of UME as Unmet Need Payer Reaction to XIPERE Profile 25 Sources: Target Ophthalmologist ATU, May 2018. | Payer Research, Precision for Medicine, Aug 2018. | N=10 Medical Directors, encompassing 114M covered lives

  26. Slide 26: Broad Applicability of SCS Injection Platform

    Broad Applicability of SCS Injection Platform Small Molecules Biologics Gene Therapy 26

  27. Slide 27: Clearside Opportunities to Leverage SCS Injection Platform

    Clearside Opportunities to Leverage SCS Injection Platform Suprachoroidal Space (SCS) Injection Platform 27 Uveitic Macular Edema NDA Submitted October 19, 2019 PDUFA Date Globalization & Label Expansion Non-infectious Uveitis DME monotherapy Platform Expansion Gene Therapy Platform Expansion Small

  28. Slide 28: Potential Label Expansion: Diabetic Macular Edema (DME)

    The Opportunity Real world data demonstrates patients missing out on visual gains Patients have variable response to anti-VEGF treatment High burden for DME patients leading to poor compliance Potential Label Expansion: Diabetic Macular Edema (DME) 28 Primary Need Improved resolution of edema and lo

  29. Slide 29: Market Size and Current Treatment Paradigm for DME

    Market Size and Current Treatment Paradigm for DME 8.3M patients Diabetic Retinopathy patients in U.S. 1.1M patients DME patients 29 Anti-VEGF Sustained release steroid Intravitreal Triamcinolone Acetonide 1 2 3 2nd Line treatment 1st Line treatment CURRENT TREATMENTS

  30. Slide 30: Treatment Burden and Patient Compliance Create Need For Options

    Treatment Burden and Patient Compliance Create Need For Options XIPERE has the potential to maintain visual gains on a quarterly dosing regimen Current anti-VEGFs require retreatment every 4 to 8 weeks Subjects gained approximately 10 letters and were maintained for 12 weeks with XIPERE + intravitre

  31. Slide 31: Potential Platform Expansion: Small Molecules and Biologics

    The Opportunity Current intravitreal treatments have diffuse distribution Protection of off-target tissues Migration of small molecules into the anterior chamber Limited duration of action Potential Platform Expansion: Small Molecules and Biologics 31 Primary Need Targeted delivery to retina with pr

  32. Slide 32: Potential Platform Expansion: Small Molecules

    Potential Platform Expansion: Small Molecules SCS Platform May Offer Unique Distribution and Better Duration 32 High drug levels achieved in retina and choroid-RPE-sclera Concentration presented as mean + SEM Based on non-clinical data

  33. Slide 33: Potential Platform Expansion: Ocular Gene Therapy

    Opportunity Avoid risks of vitrectomy (surgery) Avoid risks of retinotomy, subretinal injection, and macular detachment Potential for broader retinal coverage Enhance patient access Convert gene therapy into an office-based procedure Potential Platform Expansion: Ocular Gene Therapy 33 Primary Need

  34. Slide 34: Experienced Leadership Team

    Experienced Leadership Team 34 Clearside Team Ophthalmic Experience George Lasezkay Pharm.D., J.D. | Interim CEO and Director 30 years experience Allergan, Acucela, Novagali, Amakem, RetroSense Thomas Ciulla M.D., MBA | Chief Medical Officer 27 years experience Spark Therapeutics, Ophthotech, Indian

  35. Slide 35: Financial Summary

    Financial Summary March 31, 2019 Cash, cash equivalents and short-term investments $34,938 Total assets 37,534 Long-term debt (including current portion) 10,036 Total liabilities 21,443 Total stockholders’ equity 16,091 Common shares outstanding (as of May 6, 2019) 37,595,551 ($000’s except share co

  36. Slide 36: Clearside Biomedical: Five Key Investment Themes

    Clearside Biomedical: Five Key Investment Themes Large and growing retinal market opportunity Patented technology and delivery approach Proprietary access to the suprachoroidal space Upcoming PDUFA date in Oct. 2019 for XIPERE Partnering to monetize and expand use of SCS platform 36

  37. Slide 37: "D Sas |

    "D Sas |

Clearside Biomedical — Investor Presentation (May 2019) on 6ix